AstraZeneca eyes ambitious $80B valuation milestone by 2030. The pharma giant's growth strategy hinges on three pillars: ADC (antibody-drug conjugate) expansion, cell therapy breakthroughs, and a solid runway of near-term product launches. These aren't just pipeline dreams—the company's positioning itself to capture market share in high-margin therapeutic areas. For investors tracking $AZN, the confluence of innovative pipeline assets and near-term revenue catalysts could reshape the stock's trajectory. Whether AZN can execute on this vision while navigating regulatory hurdles and competitive pressures will be the real test.